Newly diagnosed, stage III or IV amenable to surgery, HPV negative, squamous-cell carcinoma of the oral cavity, oropharynx, hypopharynx or larynx (SCCHN) for patients who have completed and a documented complete response to gross total resection of the primary tumor and standard adjuvant therapy.

• A phase I/II trial of TG4050, an individualised gene therapy, in patients with advanced cancer of the head and neck. Recruiting
  2023-508561-33-00 7 2019-12-12

Showing 1–1 of 1 trials